Arcus kidney cancer drug shows stronger potency than Merck's Welireg, boosting shares

Arcus Biosciences reported follow‑up data from its late‑stage kidney cancer trial that suggest its experimental therapy, casdatifan, may be more potent than Merck's approved drug Welireg. Analysts highlighted the improved tumor‑progression and survival signals, calling it a potential "step‑up in potency" and noting its possible role as an all‑line backbone therapy for clear cell renal cell carcinoma.

The positive readout sent Arcus shares up about 8% on the day of the announcement, reflecting renewed investor confidence in the drug’s commercial prospects. Analysts at Leerink Partners and Mizuho Securities said the data could add significant value if the drug succeeds in first‑line settings.

In other news, TriGemX Bio announced it will go public through a special purpose acquisition company (SPAC) transaction, while Eli Lilly entered a research partnership with Hong Kong‑based METiS TechBio. Both moves underscore ongoing strategic activity in the biotech sector.